JPH0155245B2 - - Google Patents
Info
- Publication number
- JPH0155245B2 JPH0155245B2 JP57216795A JP21679582A JPH0155245B2 JP H0155245 B2 JPH0155245 B2 JP H0155245B2 JP 57216795 A JP57216795 A JP 57216795A JP 21679582 A JP21679582 A JP 21679582A JP H0155245 B2 JPH0155245 B2 JP H0155245B2
- Authority
- JP
- Japan
- Prior art keywords
- nifedipine
- present
- sample
- fatty acid
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21679582A JPS59106418A (ja) | 1982-12-13 | 1982-12-13 | ニフエジピン製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21679582A JPS59106418A (ja) | 1982-12-13 | 1982-12-13 | ニフエジピン製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59106418A JPS59106418A (ja) | 1984-06-20 |
| JPH0155245B2 true JPH0155245B2 (de) | 1989-11-22 |
Family
ID=16693991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21679582A Granted JPS59106418A (ja) | 1982-12-13 | 1982-12-13 | ニフエジピン製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59106418A (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001240534A (ja) * | 2000-02-29 | 2001-09-04 | Bio Kagaku Kk | 液状組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5420127A (en) * | 1977-07-14 | 1979-02-15 | Yamanouchi Pharmaceut Co Ltd | Solid nifedipine preparaton |
| JPS54160713A (en) * | 1978-06-05 | 1979-12-19 | Kali Chemie Pharma Gmbh | Medical preparation with improved absorbability and production |
| JPS5758609A (en) * | 1980-09-26 | 1982-04-08 | Kaken Pharmaceut Co Ltd | Drug containing nifedipine |
-
1982
- 1982-12-13 JP JP21679582A patent/JPS59106418A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59106418A (ja) | 1984-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4334869B2 (ja) | 溶解性または経口吸収性の改善された組成物 | |
| JP2856817B2 (ja) | 医薬組成物 | |
| KR101710435B1 (ko) | 칼라놀라이드, 이의 유도체 및 유사체에 대한 약학 조성물 및 이의 제조 방법 | |
| FR2737121A1 (fr) | Nouvelles formulations galeniques du fenofibrate et leurs applications | |
| JPH11512115A (ja) | 経口投与用製剤組成物 | |
| EP0152292A2 (de) | Acetaminophen-Gelatinekapseln | |
| EP2525827B1 (de) | Pharmazeutische formulierungen aus loratadin zur einkapselung und kombinationen daraus | |
| US20040229939A1 (en) | Tetrahydrocannabinol compositions and methods of manufacture and use thereof | |
| NZ539046A (en) | Chemotherapeutic self-emulsifying microemulsion compositions of paclitaxel with improved oral bioavailability | |
| GB2154874A (en) | Bromocriptine compositions | |
| MXPA04000535A (es) | FORMULACIONES ANTIHISTAMINICAS PARA FORMAS DE DOSIFICACION DE CaPSULAS SUAVES. | |
| JPH0155245B2 (de) | ||
| JP2006509785A (ja) | ビフェニルジメチルジカルボン酸の経口用マイクロエマルション組成物 | |
| WO2022072099A1 (en) | Immediate release dosage forms, methods of making and using | |
| JPS6138170B2 (de) | ||
| KR920008817B1 (ko) | 조절된 방출성(서방성) 약학적 제제의 제조방법. | |
| KR102262740B1 (ko) | 밀크시슬을 함유한 정제 조성물 및 이의 제조 방법 | |
| JPH0448776B2 (de) | ||
| KR101200169B1 (ko) | 플루비프로펜을 함유하는 고체 자가 유화 약물 전달 조성물 | |
| WO2000037083A1 (en) | Oral antiestrogen pharmaceutical composition | |
| KR20250048301A (ko) | 아비라테론 아세테이트의 경구 제형 및 이의 제조방법 | |
| JPH0665078A (ja) | リシンクロニキシネート含有医薬用軟カプセル | |
| TWI361080B (de) | ||
| JP2007505103A (ja) | 摂取された飲食物の影響を受けないイトラコナゾール経口用組成物及びその製造方法 | |
| EP1660522A2 (de) | Pharmazeutische zusammensetzung mit erhöhter bioverfügbarkeit, die sich für die verabreichung von oralen inhibitoren von retroviraler protease eignet. verfahren zur herstellung einer konzentrierten pharmazeutischen zusammensetzung, die einen inhibitor von retroviraler protease enthält |